Drug
firm Lupin said it had received approval from the U.S. health regulator to
market Levothyroxine Sodium tablets used for treating hypothyroidism. The
company has received the USFDA’s approval to market the tablets in the
strengths of 25 microgram (mcg), 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125
mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg, Lupin said.
-
.jpg)
Join us in celebrating "Vachan Sankalp Maharashtracha", a vibrant initiative to honor the joy of reading. ๐ Event Highlights: ... -
Your insights are vital! Review the draft and share your comments or suggestions to help us enhance these regulations. (Draft Regulation) ...
-
According to a new study published in Scientometrics, scientific articles that get downloaded from the scholarly piracy website Sci-Hub tend...